O
HUMA icon

OrbiMed’s Humacyte HUMA Stock Holding History

OrbiMed’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,500,000
Closed -$17.4M – 163
2021
Q3 		$17.4M Buy
+1,500,000
New +$17.2M 0.19% 104

Other funds holding HUMA

YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
DCP
Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
GIA
Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OrbiMed's HUMA Position: Q4 2021 in Review

OrbiMed sold out of Humacyte (HUMA) in Q4 2021, closing a stake of 1,500,000 shares — an estimated $17.4M sold.

OrbiMed first reported a position in HUMA in Q3 2021 and held it in 1 quarter. The position peaked at $17.4M in Q3 2021. 61 funds tracked by Wall St. Rank hold HUMA as of Q4 2021.

  • OrbiMed reported no remaining Humacyte position as of Q4 2021 after selling out during the quarter.
  • OrbiMed sold 1,500,000 Humacyte shares in Q4 2021, an estimated $17.4M.
  • OrbiMed first reported a position in Humacyte in Q3 2021 and held it in 1 quarter.
  • OrbiMed's Humacyte position peaked at $17.4M in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Humacyte as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.